Endocrinology Research and Practice
Case Report

Response of Macroprolactinemia to Dopamine Agonists

1.

Göztepe Educational and Research Hospital, Division of Endocrinology and Metabolism, İstanbul, Turkey

2.

University of İstanbul, İstanbul School of Medicine, Department of Biochemistry, İstanbul, Turkey

3.

University of İstanbul, İstanbul School of Medicine, Division of Endocrinology and Metabolism, İstanbul, Turkey

Endocrinol Res Pract 2008; 12: 83-85
Read: 1851 Downloads: 404 Published: 01 September 2008

Abstract
Macroprolactinemia, defined as hyperprolactinemia with a predominance of the big big prolactin (macroprolactin) isoform, is considered idiopathic and poorly symptomatic. Although macroprolactinemia has been considered to be a cause of apparent resistance to antiprolactinemic drugs, prolactin (PRL) normalization with dopaminergic treatment cannot exclude macroprolactinemia. We report three cases with macroprolactinemia, whose PRL and macroprolactin levels were decreased and hyperprolactinemic symptoms were improved with dopamine agonists. 

Makroprolaktineminin Dopamin Agonistlerine Cevabı

Özet
Makroprolaktineminin ileri tetkik ve tedavi gerektirmeyen selim bir durum olduğu öne sürülmesine rağmen, bazı çalışmalarda makroprolaktinemide hiperprolaktinemik sendromun klinik ve radyolojik özelliklerinin görülebileceği iddia edilmektedir. Bu görüşü destekleyen çalışmalarda, dopamin agonistiyle tedavi edilen makroprolaktinemili hastalarda total prolaktin (t-PRL) ve makroprolaktin düzeyinde düşme elde edilmiştir. Bununla birlikte, makroprolaktineminin, antiprolaktinemik ilaçlara rezistansın sebebi olduğunu iddia eden çalışmalar da mevcuttur. Burada bromokriptinle tedavi edilen üç makroprolaktinemili olgu sunulacaktır. 
Anahtar kelimeler: Makroprolaktinemi, dopamin agonistleri

Files
EISSN 2822-6135